Plain-English translation of NCT06526923 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Cystic Fibrosis research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is an early-stage trial testing a new inhaled medication called SP-101 for people with cystic fibrosis. Researchers want to understand how safe the medication is and how your body processes it. The study is designed for adults with cystic fibrosis who either cannot take or do not tolerate existing CF modulator therapies.
Many people with cystic fibrosis cannot benefit from current standard treatments because they don't work for their specific CF mutation or cause side effects they cannot tolerate. This trial is exploring whether this new medication might offer an additional option for these patients.
You likely qualify if…
You likely don't qualify if…
You would visit a study center to inhale a single dose of the medication through a nebulizer (a machine that turns liquid medicine into a fine mist). The researchers will then monitor you carefully to watch for any side effects and measure how your body handles the medication. This is a Phase 1/2 trial, meaning it starts with small groups of people at low doses and gradually increases doses as safety is confirmed, similar to how new medicines are first tested in people.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States